The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong, MD, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, discusses frontline treatment selection in mantle cell lymphoma (MCL), highlighting that there is no single standard treatment approach in the US and that decisions are guided by both disease risk and patient preference. Dr Chong explains that patients have access to a range of treatment options, including bendamustine-rituximab (BR), BTK inhibitor-based therapies, and chemotherapy-based regimens. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the most important thing is that there’s no single right approach. There are multiple approaches that are all reasonable, and it’s very patient-driven. In the US, we’re very lucky because we have multiple options for these patients, which includes an ECHO trial approach, so bendamustine, rituximab, with acalabrutinib. We have the option to do BTK with rituximab alone. We have the option to do BOVen-like approaches for TP53-mutated mantle cell lymphoma...
I think the most important thing is that there’s no single right approach. There are multiple approaches that are all reasonable, and it’s very patient-driven. In the US, we’re very lucky because we have multiple options for these patients, which includes an ECHO trial approach, so bendamustine, rituximab, with acalabrutinib. We have the option to do BTK with rituximab alone. We have the option to do BOVen-like approaches for TP53-mutated mantle cell lymphoma. There’s obviously the TRIANGLE data, so chemotherapy-based approach. And so there’s multiple approaches that we use, depending upon how high-risk that mantle cell lymphoma is, as well as patient preference. But we have access to all of those, and so I think we’re very lucky in that respect.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
